Suppression of serum insulin-like growth factor-1 levels in breast cancer patients during adjuvant tamoxifen therapy
- 31 December 1993
- journal article
- Published by Elsevier in European Journal Of Cancer
- Vol. 29 (10) , 1368-1372
- https://doi.org/10.1016/0959-8049(93)90003-x
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Tamoxifen attenuates pulsatile growth hormone secretion: mediation in part by somatostatinEndocrinology, 1992
- Direct effects of tamoxifen on growth hormone secretion by pituitary cells in vitroEuropean Journal Of Cancer, 1992
- Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapyThe Lancet, 1992
- Effect of Tamoxifen on Serum Insulinlike Growth Factor I Levels in Stage I Breast Cancer PatientsJNCI Journal of the National Cancer Institute, 1990
- Response to second-line hormone treatment for advanced breast cancer. Predictive value of ploidy determinationCancer, 1990
- Long-term adjuvant tamoxifen therapy for breast cancerBreast Cancer Research and Treatment, 1990
- Estradiol stimulates invitro the secretion of insulin-like growth factors by the clonal osteoblastic cell line, UMR106Biochemical and Biophysical Research Communications, 1989
- Adjuvant tamoxifen in postmenopausal breast cancer: Preliminary results of a randomized trialBreast Cancer Research and Treatment, 1986
- In vitro stimulation of human NK activity by an estrogen antagonist (tamoxifen)European Journal of Cancer and Clinical Oncology, 1984
- Tamoxifen is a calmodulin antagonist in the activation of cAMP phosphodiesteraseBiochemical and Biophysical Research Communications, 1984